Enllaços d'accés:
CONTINGUT
Destacados
-
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Tural, C., Tor, J., Sanvisens, A., Perez-Alvarez, N., Martinez, E., Ojanguren, I., Garcia-Samaniego, J., Rockstroh, J., Barluenga, E., Muga, R., et al.Clin Gastroenterol Hepatol 7, 339-345.
-
Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe.
Vercauteren, J., Wensing, A. M., van de Vijver, D. A., Albert, J., Balotta, C., Hamouda, O., Kucherer, C., Struck, D., Schmit, J. C., Asjo, B., et al.J Infect Dis 200, 1503-1508.
-
Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
Radi, M., Maga, G., Alongi, M., Angeli, L., Samuele, A., Zanoli, S., Bellucci, L., Tafi, A., Casaluce, G., Giorgi, G., et al.J Med Chem 52, 840-851.
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Pulido, F., Perez-Valero, I., Delgado, R., Arranz, A., Pasquau, J., Portilla, J., Rubio, R., Gonzalez-Garcia, J., Miralles, P., Perez-Elias, M. J., et al.Antivir Ther 14, 195-201.
-
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost, A., Negredo, E., Theodoro, F., Puig, J., Levi, M., Ayen, R., Grassi, J., and Clotet, B.Antimicrob Agents Chemother 53, 1937-1943.
